Combined sales of Opdivo, Orencia, Pomalyst/Imnovid, Eliquis, and Revlimid were $8.84 billion [71.6% of Bristol-Myers Squibb's total revenue] in the last three months of 2024, up 2.6% quarter-on ...

Bristol-Myers Squibb Company discovers, develops ... Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel to treat patients with ...

We recently published a list of 10 Dirt Cheap Stocks To Invest In Now. In this article, we are going to take a look at where Bristol-Myers Squibb Company (NYSE:BMY) stands against other dirt cheap ...